



The Relationship between Insulin PSTI Polymorphism and Prostate Cancer in Turkish Population

Türk Popülasyonunda PSTI Polimorfizminin Prostat Kanseri ile İlişkisinin Araştırılması

Muhammed Hamza Müslümanoğlu¹, Tanju Basmacı², Selma Demir Ulusal², Hüseyin Aslan³, Emre Tepeli⁴, Muhsin Özdemir², Mehmet Turgut⁵

¹Yıldız Technical University, Faculty of Science and Arts, Department of Molecular Biology, İSTANBUL

^{2,5}Eskisehir Osmangazi University, Faculty of Medicine, Department of Medical Genetics and Urology
ESKİŞEHİR

³Adana Numune Research and Education Hospital, Department of Medical Genetics, ADANA

⁴Denizli Pamukkale University, Medical Faculty, Department of Medical Genetics, DENİZLİ

Cukurova Medical Journal 2013; 38 (3):434-439.

ABSTRACT

Purpose: There is positive correlation between insulin and various cancers such as colon, lung and endometrium. Prostate cancer is the one of them. The aim of this study, to determine the incidence of INS+1127 *PstI* polymorphism, located in the 3' UTR of insulin gene, between prostate cancer cases and controls and to clarify if this polymorphism have any role in the etiology of prostate cancer.

Methods: We investigated 71 prostate cancer cases and 119 normal controls unrelated to patients. INS+1127 *PstI* polymorphism was investigated with PCR and RFLP method.

Results: At the end of study; INS+1127 *PstI* polymorphism genotypes out to be 67.6 % CC, 28.2 % CT, 4.2 % TT among prostatic cancer individuals and 78.2% CC, 21% CT, 0.8% TT among control group individuals.

Conclusion: As a result, there was no significant difference between patients and control group, in the genotype distribution.

Key Words: INS, polymorphism, prostate cancer, PSTI

ÖZET

Giriş: İnsülin ve kolon, akciğer ve endometrium kanserleri gibi bazı kanser türleri arasında pozitif bir korelasyon olduğu bilinmektedir. Prostat kanseri de bunlardan birisidir. Bu çalışmadaki amacımız insülin geni 3' UTR bölgesinde lokalize olan INS+1127 *PstI* polimorfizminin prostat kanseri etiyolojinde rolünü araştırmaktır.

Materyal ve Metod: Çalışmaya 71 prostat kanseri tanısı almış hasta ve 119 normal kontrol bireyi dahil edilmiştir. INS+1127 *PstI* polimorfizm araştırması için PCR ve RFLP tekniği kullanılmıştır.

Bulgular: Çalışmanın sonucunda INS geni *PstI* polimorfizmi genotipleri prostat kanserli hastalarda (n:71) %67,6 CC, %28,2 CT, %4,2 TT; kontrol grubunda (n: 119) %78,2 CC, %21 CT, %0,8 TT olarak belirlenmiştir.

Sonuç: Hasta ve kontroller arasındaki genotip dağılımında istatistiksel olarak anlamlı bir farklılık bulunamamıştır (P=0,078).

Anahtar Kelimeler: INS, polimorfizm, prostat kanseri, PSTI

INTRODUCTION

Prostate cancer is the most common cancer in the male population and a second leading cause of cancer related mortality in men¹. Although the aetiology of this disease remains largely unclear it is likely caused from complex interactions amongst endocrinological factors such as androgen metabolism, genetic factors, and environmental factors such as alcohol consumption and smoking. In addition of ethnic differences common genetic variants are a significant contributor to the risk of developing prostate cancer; in fact, of all cancer types, prostate cancer is most closely linked to genetic risk factors².

The negative effect of insulin in the aetiology of prostate cancer and lead to increased risk of prostate cancer is shown in some studies^{3,4,5,6}. Epidemiological studies show a positive correlation between insulin levels and increased risk of developing certain types of cancer, such as colon, lung and endometrium^{7,8,9,10,11,12}. Insulin has a strong mitogenic effect in prostate cells. It mediately influences androgen levels by use of regulation of sex hormone binding globulin (SHBG) levels. And also insulin directly regulates insulin-like growth factor binding proteins (IGFBPs) levels and therefore affects availability of insulin-like growth factor (*IGF-1*) (C16,17). So biological mechanism of insulin also supports its own's tumorigenic effect^{13,14,15,16,17}. Thus elevated insulin levels and insulin resistance have been implicated in prostate cancer development³.

Insulin gene (*INS*) located on chromosome 11p15.5. VNTR region of *INS* is adjacent to the 5' promoter region (5' UTR) and has a direct effect on the regulation of insulin expression¹⁸. *INS* VNTR polymorphisms are classified two main groups. First one Class I allele (28-44 repeat) and second one Class III allele (138-159 repeat). Population frequencies are 70% and 30% respectively. The medium-length class II allele is quite rare¹⁹. The VNTR allelic variants of insulin gene are associated with diabetes mellitus (DM).

For example Class I is associated with type I DM, Class III with type II DM^{20,21,22,23,24}.

While 5' UTR stimulate the pro-insulin translation, 3'UTR has negative affects on protein synthesis. So mutual interference with UTRs significantly affects biosynthesis of proinsulin. In this manner untranslated regions of mRNA has critical role in stabilisation and regulation²⁵. The *INS+1127 PstI* polymorphism is located in the 3'UTR *INS*. In the present study, we evaluated the possible association of the *INS+1127 PstI* polymorphism and prostate cancer risk.

MATERIALS and METHODS

This study was performed at the Eskisehir Osmangazi University Medical Faculty Department of Medical Genetics with a study group of 71 prostate cancer patients between the ages of 50 – 86 and a control group of 119 subjects not having prostate cancer determined by the Department of Medical Genetics based on histopathological findings. The cancerous tissue from prostate biopsies was graded according to the Gleason histopathological grading system. Gleason score ≥ 7 was accepted as high and < 7 as low grade tumors. In our study, *INS+1127 PstI* polymorphism ratio was compared among these two groups and analyzed to see if there is a statistically significant difference. Informed consent was obtained prior to participation in the study.

Molecular study

Genomic DNA of patients and control subjects was isolated from peripheral blood using QIAmp DNA Blood Mini Kit. To amplify the gene region containing the *INS+1127 PstI* polymorphism region, 5 μ L DNA was added to the mixture containing 5 μ L 10x polymerase chain reaction (PCR) buffer (P-2192; Sigma, St. Louis, MO), 5 μ L dNTP mixture (Promega, madison, WI) containing 0.2 mM of each nucleotide, 5 μ L 1 mM Tris-HCL, 5 μ L 5mM KCL, and 4 pmol of F: 5' – GGG TCC CCT GCA GAA GCG TGG CA – 3' and R: 5' – CTC CCT CCA CAG GGA CTC CAT C – 3'

primers each, and 0.2 µL Taq polymerase (D-6677; Sigma) enzyme, and was completed to 50 µL with ddH₂O. For amplification, the reaction mixture was exposed to final extension for 10 min at 72°C after the first denaturation of 3 min at 95°C and 35 cycles of 40 s at 95°C, 1,5 min at 61°C, and 1 min at 72°C. About 15 µL of the obtained 562 bp (base pair) PCR products was added to the reaction mixture composed of 7 µL bidistilled water, 5 units of PstI enzyme, and 2,5 µL buffer,

and was left to digestion for 16 h at 37°C. To separate the fragments that form after digestion, an ultra-pure agarose gel of 2% was added and 20 µL PCR products were subject to 1.5 h of gel electrophoresis. After electrophoresis, 562 bp fragments were determined to be obtained from CC genotype; 562, 470, and 92 bp fragments were determined to be obtained from CT genotype; and 470 and 92 bp fragments were determined to be obtained from TT genotype (Figure 1).




Figure1. Gel electrophoresis view of samples having INS *PSTI* CC, CT and TT alleles.

Table1: Distribution of genotypes among patients and controls

Genotypes	Patients		Controls	
	N	%	N	%
CC	48	67,6	93	78,2
CT	20	28,2	25	21,0
TT	3	4,2	1	0,8

(*p*>0.05, patients and controls)

Statistical analysis

SPSS 11.0 software package was used for the statistical analysis of the data. Pearson χ^2 test was used to compare the genotype distributions within the patient and control groups. The association between genotypes and degree of differentiation (high Gleason score versus low

Gleason score) was calculated Pearson's χ^2 test as well.

RESULTS

Seventy-one patients found to have prostate cancer were studied for INS+1127 *PstI* polymorphism, and 119 control subjects were studied for INS+1127 *PstI* polymorphism. Among

the patient and control groups, the allele frequencies for the T (mutant) allele were calculated to be 18.3% and 11.3% , respectively, and for the C (wild) allele the allele frequency were calculated to be 81.6% and 88.6%, respectively. When the study and control groups were analyzed for genotype frequencies the TT mutant genotype was determined to be 4.2% and 0.8%, respectively; CT heterozygote genotype was determined to be 28.2% and 21%, respectively; and CC wild-type genotype was determined to be 67.6% and 78.2, respectively. No statistically significant difference was found for the genotype

frequency differences among the study and control groups ($p=0.078$, $p>0.05$).

When the Gleason <7 patients and Gleason ≥ 7 patients were analyzed for the genotype frequencies the TT mutant genotype was determined to be 3% and 5,3%, respectively; CT heterozygote genotype was determined to be 24,2% and 31,6%, respectively; and CC wild-type genotype was determined to be 72,7% and 63,2%, respectively. No statistically significant difference was found for the genotype frequency differences among the two groups ($p=0.685$, $p>0.05$).

Table2: Association of INS *PstI* genotypes with Gleason category

Genotypes	Gleason <7 n=33 (%)	Gleason ≥ 7 n=38 (%)
CC	24 (72,7)	24 (63,2)
CT	8 (24,2)	12 (31,6)
TT	1 (3)	2 (5,3)

($p>0.05$, Gleason<7 patients and Gleason ≥ 7 patients)

DISCUSSION

Biological mechanism of insulin supports its own's tumorigenic effect. Pathways of IGF and insulin may play important roles in risk of prostate cancer. The role of insulin in the aetiology of prostate cancer is implicated by the observations from many studies⁵. Already epidemiological studies show a positive correlation between insulin levels and increased risk of developing certain types of cancer, such as colon, lung and endometrium^{7,8,9,10,11,12}. In the literature many studies showed association between IGF and insulin pathways genes and prostate cancer risk. Therefore, we evaluated INS+1127 *PstI* polymorphism in *INS* gene in Turkish prostate cancer patients.

The *INS* gene is localized between the insulin-like growth factor 2 (IGF2) gene and the tyrosine hydroxylase (*TH*) gene on chromosome 11p15.5. It has 3 exons. The INS+1127 *PstI* polymorphism is located in the 3'UTR *INS* gene. Untranslated regions of *INS* gene's mRNA has

critical role in stabilisation and regulation. The 3'UTR of *INS* gene suppresses translation and also stabilizes the mRNA²⁶. In this manner this polymorphism may play a direct role in altering insulin physiology which ultimately contributes to prostate carcinogenesis.

In a study by Ho et al., it was determined that the INS+1127 *PstI* polymorphism increased cancer risk in non-diabetic men who were over 55 years of age. In this study they genotyped 178 cases and 135 controls and they suggested that Black and Caucasian individuals with homozygous CC for INS+1127 *PstI* polymorphism had almost a two fold increased risk of prostate cancer as compared to those with other genotypes. The men who were homozygous CC also were more likely to be older and have a moderately to well-differentiated cancer (Gleason <7). Unlike the Black and Caucasian they observed a negative association between the CC genotype and prostate cancer among the Hispanics⁴. This might cause small sample size or a population stratification bias.

Claeys et al., investigated the potential association between diabetes, germ line variation in the *INS* gene and prostate cancer, they genotyped 466 men with and without prostate cancer for the *INS*+1127 *PstI* polymorphism. They also suggested that the *INS PstI* CC genotype is associated with prostate cancer risk in African-American men³. We observed that the results of this study were incompatible with the results of Claeys et al. Our results were also incompatible with the results of Ho et al. except the results of their Hispanic population. These changes can be based on ethnic differences.

Neuhausen et al. investigated the association of the *IGF1* CA-repeat, the insulin receptor substrate 1 (*IRS1*) G972R, the *IRS2* G1057D, and the *INS* +1127 *INS-PstI* polymorphisms and prostate cancer risk in a case-control study. They found that only the *IRS1* G972R GR/RR genotypes were associated with a significant increased risk for prostate cancer; other variants were not significantly associated. As a result they suggested that the insulin and/or insulin-like growth factor pathways have a role in the aetiology of prostate cancer. But *INS*+1127 *PstI* polymorphism was not significantly associated with a significant increased risk for prostate cancer²⁷. This study is compatible with our study for CC genotype of the *INS*+1127 *PstI* polymorphism.

We think the reasons of the detection of differential results to these studies can be inefficient determination of groups, only the questionnaire determines whether members of prostate problems for control groups and ethnic differences. The interactions of examined gene products with each other and their structures may be also contributing to differences in the results.

Our study showed that CC genotype of *INS*+1127 *PstI* polymorphism is not an individual risk factor for prostate cancer in Turkish population. But limitation of our study was the small number of patients included. To better assess the effect of the insulin gene polymorphism in the aetiology of prostate cancer, taking into

consideration the other molecules with which they interact large sample groups and different ethnic descent should be studied.

Conflict of interest statement

All the authors declare no conflict of interest.

REFERENCES

1. Barbisan F, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Kirkali Z et al. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer? *BJU Int.* 2009; 103: 1058-63.
2. Bergman M, Ahnström M, Palmebäck Wegman P, Wingren S. Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women. *J Cancer Res Clin Oncol.* 2005; 131: 439-44.
3. Claeys GB, Sarma AV, Dunn RL, Zuhlke KA, Beebe-Dimmer J, Montie JE et al. *INS**PstI* polymorphism and prostate cancer in African-American men. *Prostate.* 2005; 65: 83-7.
4. Ho GYF, Melman A, Liu SM, Li M, Yu H, Negassa A et al. Polymorphism of the insulin gene is associated with increased prostate cancer risk. *Br J Cancer.* 2003; 88: 263-9.
5. Hsing AW, Chua S Jr, Gao YT, Gentszsch E, Chang L, Deng J et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. *J Natl Cancer Inst.* 2001; 93: 783-9.
6. Stattin P, Kaaks R. Re: Insulin resistance and prostate cancer risk. *J Natl Cancer Inst.* 2003; 95: 1086-7.
7. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. *Breast Cancer Res Treat.* 1998; 47: 111-20.
8. Gamayunova VB, Bobrov YuF, Tsyrlina EV, Evtushenko TP, Berstein LM. Comparative study of blood insulin levels in breast and endometrial cancer patients. *Neoplasma.* 1997; 44: 123-6.
9. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *J Clin Oncol.* 2002; 20: 42-51.
10. Josefson D. High insulin levels linked to deaths from breast cancer. *BMJ.* 2000; 320: 1496.
11. Ruijter E, van de Kaa C, Miller G, Ruiters D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. *Endocr Rev.* 1999; 20: 22-45.

12. Stead JD, Jeffreys AJ. Allele diversity and germline mutation at the insulin minisatellite. *Hum Mol Genet.* 2000; 9: 713-23.
13. Denton RM, Tavaré JM. Does mitogen-activated-protein kinase have a role in insulin action? The cases for and against. *Eur J Biochem.* 1995; 227: 597-611.
14. Lucassen AM, Sreaton GR, Julier C, Elliott TJ, Lathrop M, Bell JI. Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. *Hum Mol Genet.* 1995; 4: 501-6.
15. Papatsoris AG, Karamouzis MV, Papavassiliou AG. Novel insights into the implication of the IGF-1 network in prostate cancer. *Trends Mol Med.* 2005; 11: 52-5.
16. Pasquali R, Casimirri F, De lasio R, Mesini P, Boschi S, Chierici R et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. *J Clin Endocrinol Metab.* 1995; 80: 654-8.
17. Strain G, Zumoff B, Rosner W, Pi-Sunyer X. The relationship between serum levels of insulin and sex hormone-binding globulin in men: The effects of weight loss. *J Clin Endocrinol Metab.* 1994; 79: 1173-6.
18. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C et al. Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. *J Clin Endocrinol Metab.* 1993; 77: 229-33.
19. Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K. Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. *Biochem J.* 1990; 270: 383-90.
20. Bennetts ST, Tood JA. Human type 1 diabetes and the insulin gene: Principles of mapping polygenes. *Annu Rev Genet.* 1996; 30: 343-70.
21. Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y et al. Insulin like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. *Eur Urol.* 2005; 47: 695-702.
22. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. *Nat Genet.* 1995; 9: 293-8.
23. Le Stunff C, Fallin D, Schork NJ, Bougnères P. The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. *Nat Genet.* 2000; 26: 444-6.
24. LeRoith D, Roberts CT Jr. The insulin like growth factor system and cancer. *Cancer Lett.* 2003; 195: 127-37.
25. van der Poel HG. Smart drugs in prostate cancer. *Eur Urol.* 2004; 45: 1-17.
26. Wicksteed B, Herbert TB, Alarcon C, Lingohr MK, Moss LG, Rhodes CJ. Cooperativity between the preproinsulin mRNA untranslated regions is necessary for glucose-stimulated translation. *J Biol Chem.* 2001; 276: 22553-8.
27. Neuhausen SL, Slattery ML, Garner CP, Ding YC, Hoffman M, Brothman AR. Prostate cancer risk and IRS1, IRS2, IGF1, and IRS1 polymorphisms: Strong association of IRS1 G972R variant and cancer risk. *Prostate.* 2005; 64: 168-74.

Yazışma Adresi / Address for Correspondence:

Dr. Muhammed Hamza Müslümanoğlu
Yıldız Technical University,
Faculty of Science and Arts,
Department of Molecular Biology,
Davutpasa Street 124, 34210 Merter/Istanbul,
e-mail: mhmuslim@gmail.com

geliş tarihi/received :15.12.2012

kabul tarihi/accepted:28.12.2012